Real world embedding
close
프로필 배경
프로필 로고

Real world embedding

  • 분류 전체보기 (422)
    • devOps (5)
    • Pharmacology (411)
      • News (8)
      • BS (402)
  • 홈
  • BS
  • devOps

SURGE Therapeutics Raises $32M Series B Financing to Advance Intraoperative Immunotherapy to Improve Cancer Patient Survival Outcomes Post-Surgery

SURGE Therapeutics, a biotech company headquartered in Cambridge, Massachusetts, has secured $32 million in Series B financing to advance its intraoperative immunotherapy programs. Leading the funding round is Bioluminescence Ventures, with participation from KdT Ventures, Piedmont Capital, and existing investors. &nbsp The raised funds will be utilized to support the clinical development of SUR..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 19.
  • textsms

CurvaFix Closes $39 Million Series C Financing Round Led by MVM Partners and Announces CEO Transition

CurvaFix, Inc., a company specializing in the development of medical devices for repairing fractures in curved bones, has successfully concluded a series C financing round, raising an impressive $39 million. Leading the funding round is MVM Partners, a renowned investment firm. In addition to this exciting news, CurvaFix also announced a change in leadership, with Mark Foster taking on the role ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 16.
  • textsms

Bausch Health Enters Into $600 Million Financing Facility With KKR

Bausch Health Companies Inc. (NYSE/TSX:BHC) and KKR have recently announced a significant financing facility agreement worth $600 million. The agreement involves Bausch Receivables Funding LP, a subsidiary of Bausch Health, entering into a non-recourse financing facility with KKR and its credit funds and accounts. This facility will be backed by specific accounts receivables originated by anothe..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 10.
  • textsms

AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination

AEON Biopharma and Priveterra have announced the arrangement of up to $125 million in financing for their proposed business combination. The funding includes $50 million from existing and new AEON investors, as well as cash from Priveterra's trust account. This funding will allow AEON to continue its development of a botulinum toxin complex for the treatment of medical conditions, including migr..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 2.
  • textsms

Augmedics Raises $82.5 Million to Accelerate Adoption of Augmented Reality Spine Surgery

Augmedics, a pioneer in augmented reality (AR) surgical navigation, has successfully closed an $82.5 million Series D financing round to accelerate the adoption of its xvision technology in spine surgery. The funding will support the company's expansion in the US market and the development of next-generation advancements for its xvision platform. &nbsp The xvision technology provides surgeons wi..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 28.
  • textsms

Auxilius Pharma Raises Seed Round of $1 Million and Commences its Clinical Program

Auxilius Pharma has raised $1 million in seed funding to develop its lead asset, AUX-001, a new medication for treating chronic-stable angina pectoris in the US. The company is developing the drug as there have been very few medications developed to address chest pain symptoms suffered by patients with underlying coronary artery disease. Auxilius plans to conduct a first-in-human exploratory pha..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 20.
  • textsms
  • navigate_before
  • 1
  • navigate_next
공지사항
  • 데이터 요청 관련 문의
전체 카테고리
  • 분류 전체보기 (422)
    • devOps (5)
    • Pharmacology (411)
      • News (8)
      • BS (402)
최근 글
인기 글
최근 댓글
태그
  • #Study
  • #cancer
  • #Safety
  • #fda
  • #Clinical Trial
  • #N/A
  • #astrazeneca
  • #Phase 3
  • #Trial
  • #FDA approval
전체 방문자
오늘
어제
전체
Copyright © 쭈미로운 생활 All rights reserved.
Designed by JJuum

티스토리툴바